1381 RESULTS
CONFERENCE COVERAGE 2006-07-28 Conference Coverage This is part 2 of our 3-part series. Also see part 1 and part 3 or download PDF. Anti-BACE Drugs Appear on Horizon On BACE inhibition, Martin Citron of Amgen in Thousands Oaks, California, noted that more than 100 patent applications h
CONFERENCE COVERAGE 2006-07-28 Conference Coverage This is part 3 of our 3-part series. Also see part 1 and part 2, or download PDF. BACE Biology: Who Are Its Handlers? Investigators are probing intensely the question of which other proteins interact with BACE. Perhaps the interacting
CONFERENCE COVERAGE 2006-07-27 Conference Coverage Famous as they are for their powerful effects throughout the body, circulating stress hormones such as the glucocorticoid cortisol still pose somewhat of a riddle when it comes to the brain. It’s clear that chronic high exposure to the
CONFERENCE COVERAGE 2006-07-27 Conference Coverage This is part 1 of our 3-part series. Also see part 2 and part 3, or download PDF. Advances in understanding BACE1, the β-secretase enzyme relevant to Alzheimer disease, stood out as a notable trend at the 10th International Conference
CONFERENCE COVERAGE 2006-07-26 Conference Coverage Designing AD trials well, drumming up the funding, and coordinating sites across the country and the world—all that would seem to be challenge enough for clinicians in the Alzheimer disease field. But even once that’s done, they don’t
CONFERENCE COVERAGE 2006-07-21 Conference Coverage The 10th International Conference on Alzheimer’s Disease and Related Disorders, ICAD for short, ended yesterday just outside the palatial capital of Spain. The conference attracted not only a record number of attendees—just above 5,000
CONFERENCE COVERAGE 2006-07-21 Conference Coverage By the wholly unscientific survey of a roving reporter, the single most convincing and surprising molecular biology story that stuck in the minds of scientists at the 10th ICAD meeting was Christian Haass ’s demonstration of a physiolo
CONFERENCE COVERAGE 2006-05-31 Conference Coverage Therapy development efforts in AD have diversified to include statins, PPARγ agonists, antioxidants, and certain NSAIDs as existing drug candidates, as well as the tau kinase GSK3β as a target for preclinical drug development. But most
CONFERENCE COVERAGE 2006-05-30 Conference Coverage The Mandelkow group has been working to generate inducible, TET-off tau-transgenic mice to extend their body of cell-based findings into in-vivo data. At the meeting, Magda Mocanu presented an initial analysis. The group had generated
CONFERENCE COVERAGE 2006-05-29 Conference Coverage Cell culture studies notwithstanding, in the brain, the presynaptic terminals of neurons are thought to be a main source of Aβ, and a controversy is simmering in the field about exactly how it gets there. One view, advanced by Larry Go
CONFERENCE COVERAGE 2006-05-26 Conference Coverage Interactions of APP with its family members APLP1 and APLP2 have complicated not only the study of its internalization and processing but also the search for its physiological function. That this is not fully understood is frequently c
CONFERENCE COVERAGE 2006-05-25 Conference Coverage Generally speaking, drug development research improves when a range of proteins becomes known that interacts with the target of choice in biologically important ways. A number of labs are now on the trail of proteins that control α-sec
CONFERENCE COVERAGE 2006-05-24 Conference Coverage Of the three major APP processing steps, the richest and most varied biology appears to lie ahead for investigators who probe α cleavage. Long dismissed as “the other” cleavage that precluded Aβ formation, it languished in the shadows
CONFERENCE COVERAGE 2006-05-23 Conference Coverage Scientists believe that of the different γ complexes that exist in vivo, some are tuned for Notch, some for APP, some to yet other substrates. This tuning probably happens during the assembly phase, implying that there must be regulati
CONFERENCE COVERAGE 2006-05-22 Conference Coverage Mechanistic studies of γ-secretase, and the search for good modulators, would make a leap forward if the scientists could simply look at the protease and see its structure. With at least 18 transmembrane domains, the complex is too fie
